Other News

Merit Medical Announces the Appointment of Joe Wright to Chief Commercial Officer

Merit’s long-time executive, Joe Wright, has been appointed to the new role of Chief Commercial Officer and will be responsible for leading all commercial activities for the global organization. SOUTH JORDAN, Utah, Nov. 01, 2022 (GLOBE NEWSWIRE) — Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer […]

Abiomed Announces Second Quarter Revenue of $266 Million, up 11% in Constant Currency*, up 7% on a Reported Basis Year Over Year

DANVERS, Mass.–(BUSINESS WIRE)–ABIOMED, Inc. (NASDAQ: ABMD), a leader in breakthrough heart, lung and kidney support technologies, today announces financial results for the quarter ended September 30, 2022. Second Quarter 2023 Financial Highlights: Revenue of $266 million, an increase of 11% in constant currency, or 7% on a reported basis. This […]

PFIZER REPORTS STRONG THIRD-QUARTER 2022 RESULTS AND RAISES 2022 OUTLOOK

Solid Third-Quarter 2022 Revenues of $22.6 Billion Due to Exceptionally Strong Growth Achieved in the Prior-Year Quarter, Revenues Declined 2% Operationally Excluding Contributions from Paxlovid and Comirnaty(1), Revenues Grew 2% Operationally Third-Quarter 2022 Reported Diluted EPS(2) of $1.51, Reflecting 6% Growth Over Third-Quarter 2021, Including a $0.15 Incremental Benefit in the […]

First Patient Enrolled in Reflow Medical’s DEEPER REVEAL IDE Clinical Study

San Clemente, CA—Reflow Medical, Inc., a medical device company focused on cardiovascular disease announces that the first patient was successfully treated and enrolled in the DEEPER REVEAL investigational device exemption (IDE) clinical trial (NCT05358353) at Advanced Cardiac & Vascular Centers (ACV) in Grand Rapids, Michigan. The Bare Temporary Spur Stent […]

Impella RP Flex with SmartAssist Receives FDA Approval to Treat Right Heart Failure

DANVERS, Mass.–(BUSINESS WIRE)–Abiomed (Nasdaq: ABMD) announces that Impella RP Flex with SmartAssist has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA), the FDA’s highest level of approval, as safe and effective to treat acute right heart failure for up to 14 days. Impella RP Flex is implanted via the […]

Cleerly Introduces Proxy Solution to Improve Heart Disease Imaging Workflows

Proxy allows for seamless data transmission and improved AI-based plaque analysis NEW YORK–(BUSINESS WIRE)–Cleerly, the company creating a new standard of care for heart disease, announced a new workflow solution to its portfolio, Proxy. Cleerly Proxy is a software that allows Cleerly to seamlessly transmit data to care providers by […]

ZOLL Awarded Diagnostic and Interventional Cardiology Catheter Agreement with Premier, Inc. for TherOx SuperSaturated Oxygen Therapy

CHELMSFORD, Mass.–(BUSINESS WIRE)–ZOLL, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that its TherOx SuperSaturated Oxygen (SSO2) Therapy has been awarded a group purchasing agreement for Diagnostic and Interventional Cardiology Catheters (DIC) with Premier, Inc., effective as of July 1, 2022. The agreement allows […]

United Therapeutics Announces Top Line Data From the EXPEDITE Study of Remodulin Induction Prior to Orenitram Therapy

A short induction of Remodulin® (treprostinil) injection allowed study subjects to reach double the typical doses of Orenitram® (treprostinil) extended-release tablets than patients who did not have a Remodulin induction SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that a preliminary […]

Verve Therapeutics Announces Publication of VERVE-101 Preclinical Data in Circulation and Presentations at the American Heart Association Annual Meeting

Verve Researchers Awarded Paul Dudley White International Scholar Award from the American Heart Association for Highest Ranked Abstract Submitted from the United States to Scientific Sessions 2022 BOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) — Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease […]